Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer

Howard M. Saul, Thomas V. Sedlacek, Paul B. Heller, John R. Glassburn, John Riva, Robert Bertoli, Mark Maslack, Jeffrey K. Lin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The use of radioactive colloidal phosphorus 32 ( 32P) in the treatment of epithelial ovarian cancer continues to be controversial. One institution's experience with the use of 32P in 30 patients with epithelial ovarian cancer was reviewed retrospectively. One hundred percent of attempts of placement of 32P intra-abdominally were ultimately successful. The complication rate was 11%. Mean clinical (asymptomatic) disease-free survival in patients with stage III ovarian cancer was as follows: 26 months based on absence of disease at reassessment surgery; 26 months based on microscopic residuum; and 30 months based on minimal (<5 mm) residuum. Mean disease-free survival in patients with early-stage (stages IC through IIC) ovarian cancer was 66 months.

Original languageEnglish (US)
Pages (from-to)727-732
Number of pages6
JournalJournal of the American Osteopathic Association
Volume96
Issue number12
StatePublished - Dec 1 1996
Externally publishedYes

Fingerprint

Phosphorus
Ovarian Neoplasms
Disease-Free Survival
Asymptomatic Diseases
Therapeutics
Ovarian epithelial cancer

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

Cite this

Saul, H. M., Sedlacek, T. V., Heller, P. B., Glassburn, J. R., Riva, J., Bertoli, R., ... Lin, J. K. (1996). Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer. Journal of the American Osteopathic Association, 96(12), 727-732.
Saul, Howard M. ; Sedlacek, Thomas V. ; Heller, Paul B. ; Glassburn, John R. ; Riva, John ; Bertoli, Robert ; Maslack, Mark ; Lin, Jeffrey K. / Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer. In: Journal of the American Osteopathic Association. 1996 ; Vol. 96, No. 12. pp. 727-732.
@article{eb9def73f63c4f52be6c72f4d3f0299d,
title = "Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer",
abstract = "The use of radioactive colloidal phosphorus 32 ( 32P) in the treatment of epithelial ovarian cancer continues to be controversial. One institution's experience with the use of 32P in 30 patients with epithelial ovarian cancer was reviewed retrospectively. One hundred percent of attempts of placement of 32P intra-abdominally were ultimately successful. The complication rate was 11{\%}. Mean clinical (asymptomatic) disease-free survival in patients with stage III ovarian cancer was as follows: 26 months based on absence of disease at reassessment surgery; 26 months based on microscopic residuum; and 30 months based on minimal (<5 mm) residuum. Mean disease-free survival in patients with early-stage (stages IC through IIC) ovarian cancer was 66 months.",
author = "Saul, {Howard M.} and Sedlacek, {Thomas V.} and Heller, {Paul B.} and Glassburn, {John R.} and John Riva and Robert Bertoli and Mark Maslack and Lin, {Jeffrey K.}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "96",
pages = "727--732",
journal = "The Journal of the American Osteopathic Association",
issn = "0098-6151",
publisher = "American Osteopathic Association",
number = "12",

}

Saul, HM, Sedlacek, TV, Heller, PB, Glassburn, JR, Riva, J, Bertoli, R, Maslack, M & Lin, JK 1996, 'Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer', Journal of the American Osteopathic Association, vol. 96, no. 12, pp. 727-732.

Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer. / Saul, Howard M.; Sedlacek, Thomas V.; Heller, Paul B.; Glassburn, John R.; Riva, John; Bertoli, Robert; Maslack, Mark; Lin, Jeffrey K.

In: Journal of the American Osteopathic Association, Vol. 96, No. 12, 01.12.1996, p. 727-732.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intracavitary use of radioactive colloidal phosphorus 32 in the treatment of epithelial ovarian cancer

AU - Saul, Howard M.

AU - Sedlacek, Thomas V.

AU - Heller, Paul B.

AU - Glassburn, John R.

AU - Riva, John

AU - Bertoli, Robert

AU - Maslack, Mark

AU - Lin, Jeffrey K.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - The use of radioactive colloidal phosphorus 32 ( 32P) in the treatment of epithelial ovarian cancer continues to be controversial. One institution's experience with the use of 32P in 30 patients with epithelial ovarian cancer was reviewed retrospectively. One hundred percent of attempts of placement of 32P intra-abdominally were ultimately successful. The complication rate was 11%. Mean clinical (asymptomatic) disease-free survival in patients with stage III ovarian cancer was as follows: 26 months based on absence of disease at reassessment surgery; 26 months based on microscopic residuum; and 30 months based on minimal (<5 mm) residuum. Mean disease-free survival in patients with early-stage (stages IC through IIC) ovarian cancer was 66 months.

AB - The use of radioactive colloidal phosphorus 32 ( 32P) in the treatment of epithelial ovarian cancer continues to be controversial. One institution's experience with the use of 32P in 30 patients with epithelial ovarian cancer was reviewed retrospectively. One hundred percent of attempts of placement of 32P intra-abdominally were ultimately successful. The complication rate was 11%. Mean clinical (asymptomatic) disease-free survival in patients with stage III ovarian cancer was as follows: 26 months based on absence of disease at reassessment surgery; 26 months based on microscopic residuum; and 30 months based on minimal (<5 mm) residuum. Mean disease-free survival in patients with early-stage (stages IC through IIC) ovarian cancer was 66 months.

UR - http://www.scopus.com/inward/record.url?scp=0030462646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030462646&partnerID=8YFLogxK

M3 - Article

C2 - 9111774

AN - SCOPUS:0030462646

VL - 96

SP - 727

EP - 732

JO - The Journal of the American Osteopathic Association

JF - The Journal of the American Osteopathic Association

SN - 0098-6151

IS - 12

ER -